A research team led by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia ...
Jun 3, 2013
0
0
Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson ...
Jun 3, 2013
0
0
Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th ...
May 31, 2013
0
0
A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent—a full 15 percent improvement ...
May 29, 2013
0
0
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell ...
May 13, 2013
0
0
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal ...
May 13, 2013
0
0
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according ...
Apr 25, 2013
0
0
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be ...
Apr 15, 2013
0
0
(HealthDay)—Thousands of Medicare cancer patients are being denied treatment at clinics nationwide because of federal budget cuts related to the so-called sequester, according to a published report.
Apr 4, 2013
0
0
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, ...
Mar 21, 2013
0
0
